{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:47Z","timestamp":1792088207135,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Glucagon\u2010like peptide\u20101 receptor agonists, such as dulaglutide, exenatide and liraglutide, are approved to treat Type 2 diabetes mellitus. Although these drugs provide substantial glycaemic control, studies in rodents have prompted concerns about the development of medullary thyroid carcinoma. These data are reflected in the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> package insert, with boxed warnings and product labelling noting the occurrence of these tumours after clinically relevant exposures in rodents, and contraindicating glucagon\u2010like peptide\u20101 receptor agonist use in people with a personal or family history of medullary thyroid carcinoma, or in people with multiple endocrine neoplasia type 2. However, there are substantial differences between rodent and human responses to glucagon\u2010like peptide\u20101 receptor agonists. This report presents the case of a woman with pre\u2010existing medullary thyroid carcinoma who exhibited no significant changes in serum calcitonin levels despite treatment with dulaglutide 2.0 mg for 6 months in the Assessment of Weekly AdministRation of <jats:styled-content style=\"fixed-case\">LY<\/jats:styled-content>2189265 [dulaglutide] in Diabetes\u20105 clinical study (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00734474).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>Elevated serum calcitonin was noted in a 56\u2010year\u2010old woman with Type 2 diabetes mellitus at the 6\u2010month discontinuation visit in a study of long\u2010term dulaglutide therapy. Retroactive assessment of serum collected before study treatment yielded an elevated calcitonin level. At 3 months post\u2010study, calcitonin level remained elevated; ultrasonography revealed multiple bilateral thyroid nodules. Eventually, medullary thyroid carcinoma was diagnosed; the woman was heterozygous positive for a germline <jats:italic><jats:styled-content style=\"fixed-case\">RET<\/jats:styled-content><\/jats:italic> proto\u2010oncogene mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The tumour was not considered stimulated by dulaglutide therapy because calcitonin remained stable throughout.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.13437","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T09:02:42Z","timestamp":1501318962000},"page":"381-385","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["No calcitonin change in a person taking dulaglutide diagnosed with pre\u2010existing medullary thyroid cancer"],"prefix":"10.1111","volume":"35","author":[{"given":"S. I.","family":"Sherman","sequence":"first","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders Division of Internal Medicine University of Texas MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. T.","family":"Kloos","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs Veracyte, Inc. South San Francisco CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Endocrinology Service Memorial Sloan Kettering Cancer Center New York NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pontecorvi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Catholic University Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"V\u00f6lzke","sequence":"additional","affiliation":[{"name":"Institute for Community Medicine University Medicine Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Harper","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vance","sequence":"additional","affiliation":[{"name":"Rocky Mountain Diabetes and Osteoporosis Center, PA Idaho Falls ID USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. T.","family":"Alston","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Usborne","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. W.","family":"Sloop","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-9570","authenticated-orcid":false,"given":"M.","family":"Lakshmanan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Eli Lilly and Company.Trulicity (dulaglutide) injection for subcutaneous use [prescribing information] 2015. Indianapolis IN USA."},{"key":"e_1_2_8_3_1","unstructured":"Astra Zeneca.Bydureon (exenatide) extended\u2010release for injectable suspension [prescribing information] 2015. Wilmington DE USA."},{"key":"e_1_2_8_4_1","unstructured":"Novo Nordisk Inc.Victoza (liraglutide [rDNA origin] injection) solution for subcutaneous use [prescribing information] 2015. Princeton NJ USA."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1001578"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0335"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2016.04.053"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2004"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.137.9.3674"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(96)00895-2"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-1272"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1210\/en.2014-1722","article-title":"Chronic toxicity and carcinogenicity studies of the long\u2010acting GLP\u20101 receptor agonist dulaglutide in rodents","volume":"156","author":"Byrd RA","year":"2015","journal-title":"Endocrinology"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2318"},{"key":"e_1_2_8_14_1","first-page":"568","article-title":"Metastatic medullary thyroid carcinoma: a case report","volume":"16","author":"Niafar M","year":"2011","journal-title":"J Res Med Sci"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2761"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12479"},{"key":"e_1_2_8_18_1","unstructured":"US Food and Drug Administration Endocrine and Metabolic Drug Advisory Committee. 2 April 2009.Novo Nordisk's Liraglutide (injection) for the treatment of patients with type 2 diabetes NDA 22\u2010341 briefing document. 4\u20102\u20102009. Available athttps:\/\/www.fda.gov\/ohrms\/dockets\/ac\/09\/briefing\/2009-4422b2-01-FDA.pdfLast accessed 3 August 2017."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347369"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0620"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318216cc6d"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093746"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.113"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1934"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2359"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0959"},{"issue":"1","key":"e_1_2_8_27_1","first-page":"A\u2010125","article-title":"The rationale, objectives, design and status of the medullary thyroid carcinoma (MTC) surveillance study: a case\u2010series registry","volume":"26","author":"Koro CE","year":"2016","journal-title":"Thyroid"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13437","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:30:01Z","timestamp":1695742201000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/dme.13437"],"URL":"https:\/\/doi.org\/10.1111\/dme.13437","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,13]]},"assertion":[{"value":"2017-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}